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Summary  
Thmmbolytic therapy improves outcome in patients with 
myocardial infarction but is associated with an increased risk 
of intracranial haemorrhage. For some patients, this risk may 
outweigh the potential benefits of thrombolytic treatment. 
Using data from other studies, we developed a model for the 
assessment of an individual's risk of intracranial haemorrhage 
during thrombolysis. 
Data were available from 150 patients with documented 
intracranial haemorrhage and 294 matched controls. 49 
patients with intracranial haemorrhage and 122 controls had 
been treated with streptokinase, whereas 88 cases and 148 
controls had received alteplase. By multivariate analysis, four 
factors were identified as independent predictors of 
intracranial haemorrhage; age over 65 years (odds ratio 2.2 
[95%CI 1-4-3.5]), bodyweight below 70 kg (2.1 [1.3-3.2]), 
hypertension on hospital admission (2.0 [1.2-3.2]), and 
administration of alteplase (1.6 [1.0-2-5]). 
If the overall incidence of intracranial haemorrhage is 
assumed to be 0.75%, patients without risk factors who 
receive streptokinase have a 0.26% probability of intracranial 
haemorrhage. The risk is 0-96%, 1-32%, and 2.17% in 
patients with one, two, or three risk factors, respectively. We 
present a model for individual risk assessment that can be 
used easily in clinical practice. 
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I n t roduct ion  
Thromboly t i c  therapy improves immediate  and long-term 
survival 1~ and quality of  l i fC in pat ients with evolving 
myocardial  infarction; however,  it also carries a small but  
signif icant risk of  severe bleeding complicat ions,  inc luding 
intracranial  haemorrhage.  A physic ian must  decide for each 
individual pat ient whether  the potent ia l  benefits of  
thrombolyt ic  therapy 6 outweigh the risk. Previous studies 
have shown that age, hypertens ion,  a h igh dose of  
thrombolyt ic  for a given body weight,  be ing female, 
previous central nervous system disease, and use of  oral 
ant icoagulants are associated with increased bleeding risk 
after thrombolyt ic  therapy. TM However ,  the numbers  of  
pat ients in each of  these studies are small and risk 
assessment in i nd iv idua l  pat ients remains  uncertain.  
In this report,  data f rom several studies ~-t~,13-23 were 
combined  to collect a larger database for statistical 
evaluation, so that  we could develop a risk profile for 
intracranial  haemorrhage that  can be appl ied to indiv idual  
pat ients to assess the appropr iateness of  thrombolyt ic  
therapy. 
Pat ients  and  methods  
Individual patient data were collected from five sources: aregistry 
ofthrombolytic therapy in the Netherlands in 1988-90, l°combined 
with data from two studies by the European Cooperative Study 
Group, ~°,~6,1~ and for participants in the GlSSI - I I  and 
International Study Group trials, ~,~3.~4 the T IMI  II trials, 7,e.~8'19 
studies by the TAMI groupf1,2°-23 and the ISAM study. ~5 
In the Netherlands 2469 patients receiving thrombolytic therapy 
in 61 hospitals were registered prospectively during 18 months in 
1988-90. The registry sought o collect all patients who received 
thrombolytic therapy for evolving myocardial iflfarction. ~° No 
specific entry or exclusion criteria and no formal criteria for 
administration of thrombolytic therapy were' applied~ However, 
treatment ofpatients aged 75 years and older and treatment s arting 
later than 6 h after symptom onset was unusual at that time. Most 
patients received streptokinase, usually with aspirin and 
intravenous heparin. 24 patients were identified who developed 
intracranial haemorrhage within 48 h of the start of thrombolytic 
therapy, and complete data were available for 22 of them. We also 
included 2 patients who had intracranial haemorrhages at the 
Thoraxcenter, Rotterdam, and 7 patients of 722 treated with 
alteplase in two studies by the European Cooperative Study 
Group. mr7 Full details have been presented elsewhere3 ° 
In the GISSI-2 and International Studies, complete data were 
available for 20 768 patients who were randomly assigned either 1 "5 
MU streptokinase or 100 nag alteplase. That study had no age limit 
but patients with a history of cerebrovascular events in the 
preceding 6 months were not eligible, t3 All patients received 
aspirin and half received subcutaneous heparin, starting 12 h after 
initiation of thrombolytic therapy. Strokes were reported in 236 
patients (1-14%), of which 100 were of embolic origin, 74 were 
haemorrhagic, and 62 could not be classified, t'
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NL and ECSG GIS$1-2 TIMI TAMI ISAM Combined tdala 
ICH C ICH C ICH C ICH C ICH C ICH C 
fl 
No (%) .male 
Mean (SD) age In yr 
Infarct location* 
Anterior 
inferior 
Inferoposterior 
Lateral 
Unknown 
31 62 74 142 27 54 14 28 4 8 150 294 
27 (57) 48 (77) 47 (63) 112 (79) 16 (60) 43 (80) 7 (50) 23 (87) 2 (50) 66 (75) 98 (65) 52 (79) 
65 (8) 58 (10) 66 (11) 60 (12) 63 (8) 66 (9) 65 (7) 54 (12) 63 (8) 58 (12) 65 (8) 58 (11) 
14 19 25 59 15 30 5 11 3 3 62 122 
16 38 12 26 12 24 9 17 1 5 50 110 
10 24 . . . . . . . .  10 24 
5 11 . . . .  5 11 
1 3 37 57 .. .. 36  60  
l'nrcroboly6c droll 
Streptokinase 15 35 30 79 4 8 49 122 
Alteplase 10 20 44 63 27 54 7 11 .. 88 148 
(pro.)Urokinase 3 6 . . . .  4 6 . . . .  7 12 
Alteplase + urak inase  . . . .  3 11 . . . .  3 11 
Anistraplase 3 ' :t . . . . . . . . . .  3 1 
NL= Netherlands Registry; ECSG = European Cooperative Study Group;" GISSI-2 = Gruppe Italiaoo per io Studio della Soprawivenza nell 'lnfarto Miocardico Band the International Study 
Group;l'."," TIMI = Thrornbolysis inMyocardial infarction, phase II;' TAM I = Throrobolysis and Angioplasty in Myocardial Infarction; '."~=' ISAM = Intravenous Streptokinase inAcute Myocardial 
infarction." . • 
• Different criteria were used by the various tudy groups; in some patients multiple infarct locations were reported simultaneously. 
Table 1: Baseline data fo r /50  patle.ts with Intracerebral haemorrhage (ICH) and 294 matched controls (C) 
In the TIMI  phase II pilot study and clinical trial, 908 patients 
were treated with 150 mg alteplase and 3016 patients with 100 mg 
alteplase, both in combination with heparin and aspirin, ta,19 
Intracranial haemorrhages were observed in 27 patients (23 
intracerebral, 4 subdurape), of whom 14 had received 150 mg 
alteplase and 13 had received 100 rag. The TIMI studies enrolled 
patients up to the age of 75 years. Initially, patients with a history of 
active cerebrovascular disease during the previous 6months were 
not eligible. After revision of the protocol, ~all patients with a 
history of stroke were excluded, as well as patients with blood 
pressures above 180 mm Hg systolic or 110 mm Hg diastolic at 
presentation. At first, aspirin 80 mg was started on the same day as 
thrombolytic therapy. The protocol was revised, and in most 
patients (3297) aspirin was not started until the next day. Heparin 
was given as a 5000 IU bolus at the start of alteplase infusion, and 
continued at 1000 IU per h. Subsequently, the dose was adjusted to 
maintain the activated prothrombin time (APTT) between 1.5 and 
2.0 times control. After day 6, intravenous heparin was replaced by 
subcutaneous heparin and aspirin was increased to 325 mg 
daily.e.15.16 
The TAMI studies 9a°-13 enrolled 1619 patients up to 75 years of 
age, excluding those with recent (6 months) trauma, recent major 
surgery or active internal bleeding, known structural brain disease 
including turnout or arteriovenous malformation, stroke within 
the previous 6 months, and uncontrolled hypertension (diastolic 
pressure > 120 mm Hg by several measurements). Strokes were 
reported in 31 patients, 14 of whom had intracranial haemorrhage 
(0.9% of all patients). Thrombolytic therapy consisted ofalteplase, 
in doses of 64-150 rag, plus urokinase (1.5-2.0 MU) or 3 MU 
urokinase alone in some of the patients. Heparin infusion was 
started uring diagnostic and interventional cardiac atheterisaton, 
and maintained continuously for a minimum of 24 h, adjusted to 
maintain APTT between 1.5 and 2'0 times baseline. Aspirin was 
started uring thrombolytic therapy and continued at 325 mg daily 
together with dipyridamole 75 mg 3 times daily. 
The ISAM study Is enrolled 1741 patients. The age limit was 75 
years. Reasons for exclusion were known haemorrhagic diathesis, 
use of anticoagulants, severe treatment-resistant hypertension 
(systolic />200 mg Hg, diastolic /> 120 mm Hg), trauma, stroke, 
acute headache, visual disorders of unknown origin, trauma, or 
increased gastrointestinal bleeding risk. Intracranial haemorrhage 
was reported in 4 patients. All patients received streptokinase 1.5. 
MU in 1 h, as well as methylprednisolone, i travenous a pirin 500 
mg and heparin, followed by phenprocoumon forat least 3 weeks. 
For each patient in these studies with intracranial haemorrhage, 
2 controls were selected from the same population. The controls 
were patients treated in the same hospital, immediately before and 
after each patient with intracranial haemorrhage. For all cases and 
controls we recorded sex, age, body weight, the presence of 
insulin-dependent diabetes mellitus, vascular disease (history of 
intermittent claudication or vascular bruits before admission), 
hypertension before admission (patients receiving at least one 
antihypertensive drug), the use of anticoagulants before admission, 
smoking status, hypertension admission (systolic >i 165 mm Hg, 
diastolic /> 95 mm Hg, or both). We also recorded whether the 
patient received heparin, antiplatelet drugs, and anticoagulants 
during the hospital stay. 
Differences in clinical characteristics between patients with 
intracranial haemorrhage and controls were expressed ascrude or 
univariate odds ratios with 95% CI. Multivariate logistic 
regression analysis was done with the BMDP statistical package. 
All variables and interaction terms were entered into the model. 
All patients Alteplase-traated patients Streptoklnaso-tmated patients 
ICH + ICH - Odds ratio ICH + ICH - Odds ratio ICH + ICH - Odds ratio 
(95% CI) (95% CO (95% Cl) 
Age >65 yr 82/173 68/270 2.7 (1 8-4.0) 52/93 42/166 3~7 (2.2--6.4) 25/75 25/96 1.4 (0.7-2-8) 
Weight <70kg 76/171 74/272 2.1(1.4-3.2) 51/99 43/160 2.9(1.7--4-9) 25/71 25/100 1.6(0-8-3-2) 
Female 52/113 98/330 20 (13-3.1) 39/67 55/192 3.5 (1.9-6-2) 12/44 38/127 0.8 (0.4-19) 
Previous hypertension 63/158 84/270 15 (10-22) 42/99 51/151 1'4 (0'9-24) 19/57 29/108 14 (0"7-2'7) 
Hypertension i hospital 49/108 100/334 1-9 (1-2-3-0) 27/56 66/202 1.9 (1.1-3-5) 19/48 31/123 1.9 (1.0-39) 
Vascular disease 6/12 65/202 2 1 (0-6-6.8) 4/8 46/142 2.2 (0.5-9.0) 1/3 15/48 1-1 (0.1-131) 
Diabetes 19/52 129/386 1.1 (06-2.1) 1! /31  82/226 1.0 (0-4-2.1) 7/20 42/148 1-4 (0.5-3.6) 
Smoking 58/208 88/218 0'6 (0"4-0-9) 35/120 56/126 05 (0.3-0"9) 20/83 29/84 06 (0.3-1.2) 
History of coumadin treatment 5/8 71/218 35 (08-15 O) 50/152 3/6 17/55 22 (04-122) 
Coumadin in hospital 6/31 54/161 0.4 (0-2-1-1) ' 3/13 33/97 016 (0.2-2.3) 2/17 16/42 0.2 (0.0-1-1) 
Aspirin in hospital 46/171 41/78 03 (02-06) 29/118 26/48 0.3 (0.1-0.6) 15/47 11/23 0.5 (0.2-1.4) 
Heparin in hospital 70/203 39/118 11(0.7-17) 50/144 18/49 0.9(0-5-1.8) 16/49 19/66 1.2(0.5-2.7) 
ICH + : the number of intracranlal haemorrhages among patients with a characteristic and ICH- = the number in patients without that characteristic, 
Table 2: Olstrlbution of risk factors for Intracranlal haemorrhage, Incidence of Intracranlal haemorrhage, and unadjusted 
odds ratios 
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ICH + ICH- Adjusted odds 
ratio (95% CI) 
Age > 65 yr 77/168 66/261 2 2 (1 4-3.5) 
Weight < 70 kg 76/170 67/259 21  (13-32)  
Hypertension on admission 46/100 97/325 20  (12-3 2) 
AIteptase 93/258 50/171 1.6 (10-2.5) 
Table 3: Incidence of intracranlal haemorrhage and adjusted 
odds ratios in 429 patients with complete data 
With step-up and step-down procedures we selected the variables 
that contributed independently to the risk of intracranial 
haemorrhage (p < 0.05). The initial analysis included all patients 
with complete data sets to detect independent risk factors. 
Subsequently, the analysis was done with the larger number of 
patients for whom data on the risk factors retained in the initial 
analysis were complete. Data were presented as adjusted odds 
ratios with corresponding 95% CI. By Bayes' rule~ probabilities 
were calculated for intracranial haemorrhage in four patient groups 
with no, one, two or three risk factors, respectively. 24 
Resu l ts  
Data were available for 150 patients witl~ intracranial 
haemorrhage and 294 matched controls. The other 6 control 
patients had incomplete data. The series consisted of 145 
patients with intracerebral b eeding and 5 with subdural 
haematoma. Diagnosis of intracranial haemorrhage was 
confirmed by computed tomography inmost patients, and 
in others by necropsy or clinical findings. The mean age was 
significantly higher (p < 0.00001) in the patients with 
intracranial haemorrhage than in the controls (table 1). 
There was also a significant difference between the groups 
in the proportion of women (p = 0.002). Infarct location was 
classified in different ways by the four study groups. 
Nevertheless, we found no differences in infarct location 
between the patient groups. In particular, no excessive 
bleeding risk was apparent in patients with anterior 
infarction. The incidence of documented intracranial 
haemorrhage was 0'9 (0-6-1.3)% in the registry from the 
Netherlands, 1.0% in the two trials by the European 
Cooperative Study Group, 0-4% in the GISSI-2 and 
International Studies (with another 0.3% unclassified 
strokes), 1.5% in T IM I  patients receiving 150 mg alteplase 
and 0.4% in those receiving 100 mg alteplase, 0.9% in the 
TAMI  studies, and 0.5% in the ISAM study. Our study 
could not investigate he risks of intracranial haemorrhage 
with all the thrombolytic regimens included. Nevertheless, 
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Figure: Probability of Intracranial haemorrhage in patients with 
O, 1, or 3 risk factors 
Vertical bars= 95% CI. 
Rllk Incidence Ukellhood Probability of Intracranlal bleeding 
factors* (%)t ratio¢ (95% Cl) In % 
Incidence = 0 50 Incidence= 0.75 
53' 0.34 0-17 (010-0 27) 0.26 (0-15-0.41) 
:!. 31 128 0.64 (O 47-0.88) 0.96 (0.70-1.32) 
2 15 1,77 0.88 (0.60-1.28) 132  (0.92-1.91) 
3 1 2.89 1.43 (061-3 31) 2.17 (0.92-4.83) 
*Risk factors: age/> 65 years, body weight < 70 kg, hypertension on admission, and the use 
of an alteplase regimen, t Derived from studies by European Cooperative Study Group. ".t~ 
t Probability of finding the risk profile among patients with intracranial bleeding divided by 
probability of finding the same risk profile among patients without intracranial bleeding. 
Probability of intracranial bleeding was calculated from overall incidence and likelihood ratio 
with Bayes' rule. 
Table 4: Probability of intracranial haemorrhage after a 
thrombolytle regimen as used in these studies 
it was apparent that a greater proportion of patients who 
had intracranial haemorrhages had received alteplase in 
various doses, whereas more controls had received 
streptokinase (table 1). 
The distribution of possible risk factors for intracranial 
haemorrhage is given in table 2. Advanced age, low body 
weight, female sex, and high blood pressure were associated 
with an increased risk of intracranial bleeding. Among the 
five patient series trends were similar, although many were 
not statistically significant within different series because of 
small patient numbers. Odds ratios were greater than 2-0 in 
all series for age and body weight and in 4 of 5 for female sex. 
Few patients were taking coumadin or had a history of 
peripheral vascular disease, and no significant association 
with intracranial b eeding could be detected. Smoking was 
associated with a reduced intracranial bleeding risk. 
Furthermore, there was an apparently reduced risk 
associated with the use of aspirin in hospital, as well as with 
the use of coumadin in hospital, in the two series for which 
these data were available. 
For most risk indicators the association with intracranial 
haemorrhage was stronger among alteplase than among 
streptokinase r cipients (table 2). For example, among 
patients treated with streptokinase, the dose indices (dose/ 
body weight) in patients with intracranial haemorrhage and 
in controls were, respectively, 28 409 (7012) and 30 600 
(6308) IU/kg (p = 0"40). The corresponding dose indices for 
alteplase were 1.61 (0'37) and 1.46 (0.31) mg/kg (p < 0.01). 
After exclusion of T IM I  II patients who received 150 nag 
alteplase, the dose indices were 1.48 (0.24) mg/kg and 1.37 
(0-21) mg/kg (p < 0.01). 
Multivariate logistic regression analysis howed that four 
factors known at hospital admission were related to risk of 
intracranial haemorrhage--age ov r 65 years, weight under 
70 kg, hypertension  admission (systolic /> 170 mm Hg, 
diastolic >/95 mm Hg, or both), and drug regimens with 
alteplase in the doses used. The results of this analysis 
were similar for patients who had all data available (not 
shown) as well as for 429 patients (including 143 with 
intracranial haemorrhage) who had complete data for the 
variables retained in the multivariate model (table 3). 
Exclusion of patients with subdural haematoma did not 
affect the results. The analysis was repeated in various 
subgroups. In 258 patients who received alteplase the odds 
ratios for age, low body weight, and hypertension were 3.2 
(1.8-5.6), 2.5 (1-4--4.4), and 2.0 (i .0-3-9), respectively. The 
corresponding odds ratios in 171 patients who received 
streptokinase were 1"3 (0-7-2"0), 1-6 (0'8-3'1), and 1.9 
(0.9--4-0) (figure). Since the administration of 150 mg 
alteplase has been linked to excessive intracranial b eedingfl 
we repeated this analysis after exclusion of patients who 
received such therapy. In the remaining 220 alteplase 
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Age (yr) 
<65 66-75 76-85 >85 
~harr~kf~tom* 
0 03  1.0 1.5 2.3 
1 10  1.3 20  2.9 
2 13  2.2 3.3 5.0 
Based on data in table 4, with following assumptions: overall incidence of intracranial 
haemorrhage= 0 75%; risk at ate 76-85 is 5096 greater than at age 66-75; risk in patient 
> 85 years is again 50% greater than at 75-85. *Hypertension on admisison, low body 
weight, and use of alteplase. 
Table 5: Assessment of risk of Intracranlal haemorrhage in 
different age groups 
recipients the odds ratios were 3"3 (1.8-6.2), 2.5 (1.4--4.7), 
and 1-6 (0-8-3.4), respectively. 
From the data in table 3, we developed a model to predict 
the risk of intracranial haemorrhage in an individual patient 
(tables 4and 5). The odds ratios for the different risk factors 
were similar. Accordingly, these risk factors were given 
similar weights in the model and patients were grouped 
having one, two or three, and four risk factors. Assuming a
0.75% overall intracranial b eeding risk, the individual risk 
estimate varies from 0.26 % for a patient without risk factors 
who received streptokinase to 5-0% for an elderly 
hypertensive patient with low body weight treated with 
alteplase. 
Discuss ion  
Haemorrhagic stroke accounts for 10-15 % of all strokes in 
the general population. 2s26 Risk factors for haemorrhagic 
stroke include advanced age, hypertension, trauma, 
vascular malformations, and the use of anticoagulants.2S.27 
Most trials of anticoagulant drugs have excluded patients 
thought o be at high risk of intracranial haemorrhage, 
either by protocol or by prudent physicians when 
established risk factors were recognised. Nevertheless, 
thrombolytic therapy seems to be associated with an 
increased incidence of intracranial haemorrhage, albeit 
with a concomitant reduction in embolic stroke rates, t 2 
About half of all strokes after myocardial infarction are 
haemorrhagic when thrombolytic therapy is used. TM 
The risk factors for embolic stroke and intracranial 
bleeding differ. Patients at increased risk of embolic stroke, 
especially those with large anterior infarctions, hould not 
be denied thrombolytic therapy. In fact, thrombolysis 
specifically indicated for such patients, since it gives the 
greatest survival benefit in patients with larger infarcts. 1-3 
Limitation of infarct size and the thrombolytic effect do 
reduce the risk of left ventricular thrombi. On the other 
hand, risk factors for haem0rrhagic stroke that can be 
recognised at hospital admission should be taken into 
account when a decision is made to administer a 
thrombolytic drug to a given patient. 
Various features were found to be associated with the risk 
of intracranial haemorrhage in the studies included in our 
analysis. To obtain a larger database, the data were 
combined in our investigation. By multivariate logistic 
regression, four factors were independently associated with 
intracranial bleeding. Advanced age and high blood 
pressure are patient characteristics readily discernible 
before the decision on whether to give thrombolytic therapy 
is made. The associations with body weight and the use of 
alteplase mean that the choice of thrombolytic regimen 
must take into account he body size of a patient. Several 
other characteristics, which are known risk factors for 
intracranial haemorrhage in population studies, were 
associated with the disorder in univariate analysis but did 
not seem to have independent predictive value in 
multivariate analysis. For example, therapy with coumadin 
was associated with intracranial haemorrhage in the series 
from the Netherlands (odds ratio 3'7 [0.8-16.5]) where such 
therapy is practised in many patients with a previous 
infarction. 1° Similarly, a history of peripheral vascular 
disease or diabetes i likely to be associated with intracranial 
haemorrhagefl 2 but these findings were rare and the 
associations were not powerful enough to appear in the 
multivariate analysis. 
The association between age over 65 years and risk .of 
intracranial haemorrhage was apparent even though some 
studies excluded patients over 7016a7 or over 75. ta-2~ In 
larger population surveys of stroke, rates increase with 
age. 2a In such surveys embolic or thrombotic strokes are 
most frequent, although few surveys make a distinction 
between different ypes of stroke. Accordingly, the data 
presented in table 5 were calculated with the assumption 
that risks for intracranial haemorrhage during thrombolytic 
therapy increase with age in the same way as total stroke risk 
in the population. 
High blood pressure on admission was a stronger 
predictor of intracranial haemorrhage than a history of 
hypertension (table 2). This finding suggests that the 
bleeding risk depends not only on the state of the 
intracranial vessels, but also, and predominantly, on the 
actual blood pressure at the time of thrombolytic therapy. 
This notion is consistent with the observation that, at the 
time of hospital admission, more patients with intracranial 
haemorrhage than with other types of stroke showed high 
blood pressure. 26Prompt correction of high blood pressure 
is recommended in all infarct patients, but especially before 
or during thrombolytic therapy to reduce risk of bleeding. 
Low body weight was associated with increased risk of 
intracranial haemorrhage in patients treated with alteplase. 
GISSI-2 and the International Study Group did not find 
an association between body-mass index and haemorrhagic 
or all strokes in patients receiving thrombolytic therapy. It
However, body-mass index is a measure of the extent of 
obesity, not actual weight or total body mass. Reanalysis of 
GISSI-2 and International Study Group data confirmed 
the association between intracranial haemorrhage risk 
and body weight for patients receiving alteplase, whereas 
no relation was observed in streptokinase recipients 
(A P Maggioni, M G Franzosi, personal communication). 
Weight-adjusted dosing for alteplase has been 
recommended previously, and has been introduced in 
clinical practicefl ~,22 although "front-loaded" alteplase 
regimens use a fixed dose schedule. 29Our analysis implies 
that weight-adjusted dosing should also be considered for 
streptokinase. Future analysis of data from the GUSTO 
study may help to resolve this issue, a° 
Previous tudies howed that intracranial haemorrhage is 
more common among patients treated with "standard" 
doses of alteplase ~x or duteplase 2 than in those given 
streptokinase. These observations are supported by our 
analysis (table 3). These figures correspond to the actual 
drug regimens used in the studies. Alteplase was given in 
most patients as a fixed dose of 100 mg over 3 h. This dose 
was selected from studies that showed more rapid coronary 
reperfusion in comparison with lower doses and with 
standard streptokinase, al-a3 It is not surprising that a 
regimen with greater thrombolytic efficacy results in more 
frequent side-effects, including intracranial haemorrhage. 
If patients are treated with alteplase, the bleeding risk can  
be reduced by lowering the dose. Administration of 50 mg 
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alteplase, for example, gives the same coronary reperfusion 
rate as 1"5 MU streptokinase. 31'32 However,  the survival 
benefits of that regimen have not been established. Still, an 
increased risk of intracranial haemorrhage would be 
acceptable if the survival benefits of  such an intensive 
regimen exceeded those of a more moderate streptokinase 
regimen. The  net clinical benefit  should be positive. In  
IS IS-2f l  the number  of  survivors without neurological 
sequelae was slightly h igher (although not signif icantly so) 
in duteplase recipients than in streptokinase r cipients. 2 On 
the other hand,  in G ISS I -2  the net clinical benef i t  was 
somewhat greater for streptokinase. 1s,14 In the GUSTO 
trial, the greatest net clinical benefit  was found for the 
accelerated alteplase regimen, despite a greater rate of  
intracranial haemorrhage in comparison with two 
streptokinase r gimens.3° 
In addit ion to the thrombolyt ic  agent, most  pat ients 
receive an inhib i tor  of platelet aggregation (aspirin) as well 
as an ant icoagulant (heparin,  either intravenously or  
subcutaneously).  In our  analysis, ne i ther  aspir in nor  
heparin given in hospital was associated with risk of  
intracranial  haemorrhage,  probably  because the study 
protocols delayed use of these drugs unti l  several hours  
after thrombolysis.  Obviously, aspir in and hepar in  would 
be withheld if signs of intracranial  haemorrhage became 
apparent  in the first hours after init iat ion of thrombolyt ic  
therapy. 
Risk assessment  
The model presented in tables 4 and 5 may help a doctor to 
estimate the risk of intracranial  haemorrhage in a given 
patient. I f  the overall risk of intracranial  haemorrhage is
0.75%, the risk would be as low as 0.26% in pat ients 
without risk factors, who met  the entry and exclusion 
criteria of the studies in this analysis. The  probabi l i ty  of  
intracranial haemorrhage increased with the number  of risk 
factors present.  I f  the overall risk of intracranial  
haemorrhage is lower (0 '50%),  the risks would be 0,88% 
and 1.43% in pat ients with two or three risk factors, 
respectively. The  risks should be mult ip l ied by 1.6 i f  the 
thrombolyt ic  to be used is alteplase (figure). 
Th is  assessment of intracranial  haemorrhage risk is 
somewhat c rude,  and does not account for factors that  are 
likely to increase the risk a l though present in a smal ler 
subgroup of patients,  such as a history of  extensive 
peripheral  vascular disease, diabetes, and use of  oral 
anticoagulants. The  studies included enrol led pat ients 
younger than 75 years, with the exception of G ISS I -2  and 
the Internat ional  Study Group.  Since the risk of  
intracranial  haemorrhage increases with age, the risk in 
patients aged 75-85 years should be est imated as 1.5 t imes 
greater than that in pat ients of 65-75 years and 50% higher  
again in pat ients above 85 years of age 2a (table 5). 
Fur thermore ,  in these and all other  studies of  thrombolys is ,  
patients with recognised excessive risk of intracranial  
haemorrhage were excluded either by protocol,  or by the 
doctors responsible for their  t reatment.  Nevertheless,  
groups of  pat ients with different risk profi les can be 
dist inguished for indiv idual  clinical decis ion-making with 
the aid of our  model.  
Conclusion 
In pat ients with evolving myocardial  infarct ion 
thrombolyt ic  therapy salvages part  of the myocard ium at 
risk and improves urvival. However,  in a small number  of 
patients thrombolyt ic  therapy causes intracranial  
haemorrhage,  which often results in death or disabil ity. In 
each pat ient the doctor  should est imate the potential  
benefits and risks of  thrombolyt ic  therapy. Earl ier studies 
addressed the quest ion of  which pat ients will benef it  f rom 
thrombolysis.  6 Th is  report  identif ies the factors associated 
with increased risk of  intracranial  haemorrhage- -advanced 
age, hypertens ion upon admission,  low body weight, and 
thrombolys is  with cur rent  alteplase regimens. 
Thromboly t i c  therapy should nevertheless be given to 
elderly and hypertens ive pat ients if the expected benefits 
are great- -eg,  in pat ients with extensive (anterior) 
ischaemia who can be t reated soon after symptom onset. TM 
A careful evaluation of the applicabi l i ty thrombolyt ic  
therapy is warranted in pat ients with several risk factors for 
intracranial  haemorrhage.  
We thank all investigators who contributed mthe studies included in this 
report. 
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Moclobemide 
Hugh Freeman 
Background,  ,. 
To understand the development of moclobemide,  a
selective monoamine oxidase inhibitor (MAOI )  for use in 
depression, we need to consider its origins in 
antituberculosis drugs. Thus,  iproniazid was noted to cause 
euphoria 1 in tuberculous patients, but  this reaction was 
thought to be a response to their poor physical state. K l ine 's  
proposaP that these drugs were in fact ant idepressant was 
an important landmark in psychiatry, since the only 
effective treatment for depression unti l  then was 
electroconvulsive therapy. The i r  action in brain led to the 
agents being descr ibed as MAOIs ;  they came into clinical 
use in 1959, the same year as the first tricyclic 
antidepressant (TCA),  imipramine. 
Iproniazid had to be wi thdrawn because of  an association 
with acute hepatic necrosis (the mechanism of  which is still 
unclear) and was replaced by isocarboxacid and phenelzine. 
In the 1960s the toxic effects result ing f rom absorpt ion of  
dietary tyramine ("cheese reaction") became apparent;  his 
reaction was the result of  inhibit ion of  intestinal MAP,  
which can provoke a hypertensive crisis. T rany lcypromine 
(a non-hydraz ine MAOI  related to amphetamine)  was the 
most troublesome drug in this respect but also the most  
efficacious. In addit ion, MAOIs  were incompatible with 
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drugs containing indirectly acting sympathomimet ic  agents 
and with most forms of  alcohol. 
Two early trials showed that results with phenelzine were 
not significantly different f rom those with placebo in 
depressed patients, but the experience of  many clinicians 
was far more positive and the trial results may have come 
about because the max imum dose was too low and the 
per iod of treatment too short. Because MAOIs  then had to 
be prescr ibed with dietary and other restrictions interest 
shifted away, and their clinical use virtually ceased in most  
countries. However,  some researchers proposed that 
"atypical"  forms of depression responded better to MAOIs  
than to TCAs.  A l though the evidence remains uncertain,  
there is no doubt that individuals vary in their response to 
antidepressants, and that some with typical endogenous 
depression who do badly with TCAs  may be greatly 
improved by MAOIs .  Th is  response may be related to the 
fact that MAOIs  increase blood concentrations of 
serotonin, whereas TCAs  lower them. 2Inhibit ion of  MAP 
decreases the metabol ism of noradrenal ine and serotonin, 
leading to increased concentrations of these 
neurotransmitters.  MAOIs  have also been shown effective 
in controll ing anxiety disorders,  but this action has not been 
evaluated adequately. 
The  classic MAOIs  were irreversible in that body 
concentrat ions of MAP did not return to normal unti l  2 
weeks after the end of  t reatment because new enzyme had to 
be synthesised. Consequent ly,  drugs that might  cause toxic 
interactions, including TCAs ,  could not be introduced 
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